PDCD1 and intrahepatic cholangiocarcinoma: Interestingly, among all the patients receiving anti-PD1, the ICC group achieved a mOS of 15.1 months, while the Others group achieved a mOS of 10.7 months (HR: 1.85, 95% CI: 1.11–3.07, p = 0.02); the ICC group achieved a mPFS of 9.5 months, while the Others group achieved a mPFS of 6.2 months (HR: 1.77, 95% CI: 1.11–2.81, p = 0.02) (Figures 2A, B; Supplementary Table S1).